The global landscape of tuberculosis therapeutics

Research output: Contribution to journalReview article

Abstract

Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.

Original languageEnglish (US)
Pages (from-to)105-120
Number of pages16
JournalAnnual Review of Medicine
Volume70
DOIs
StatePublished - Jan 27 2019

Fingerprint

Tuberculosis
Pharmaceutical Preparations
Extensively Drug-Resistant Tuberculosis
Latent Tuberculosis
Therapeutics
Pipelines
Infection
Communicable Diseases
Meta-Analysis

Keywords

  • dose optimization
  • drug resistance
  • latent tuberculosis infection
  • tuberculosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The global landscape of tuberculosis therapeutics. / Tornheim, Jeffrey; Dooley, Kelly Elise.

In: Annual Review of Medicine, Vol. 70, 27.01.2019, p. 105-120.

Research output: Contribution to journalReview article

@article{9d8233c1dd7c44328364b1cd3aebdef2,
title = "The global landscape of tuberculosis therapeutics",
abstract = "Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.",
keywords = "dose optimization, drug resistance, latent tuberculosis infection, tuberculosis",
author = "Jeffrey Tornheim and Dooley, {Kelly Elise}",
year = "2019",
month = "1",
day = "27",
doi = "10.1146/annurev-med-040717-051150",
language = "English (US)",
volume = "70",
pages = "105--120",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - The global landscape of tuberculosis therapeutics

AU - Tornheim, Jeffrey

AU - Dooley, Kelly Elise

PY - 2019/1/27

Y1 - 2019/1/27

N2 - Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.

AB - Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.

KW - dose optimization

KW - drug resistance

KW - latent tuberculosis infection

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85060577065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060577065&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-040717-051150

DO - 10.1146/annurev-med-040717-051150

M3 - Review article

VL - 70

SP - 105

EP - 120

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -